ReviewACS omega2024
Exploring the Prospects and Challenges of Fluorine-Free Firefighting Foams (F3) as Alternatives to Aqueous Film-Forming Foams (AFFF): A Review.
Review in ACS omega, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed.
- PFAS Uptake by Plants in Soils Amended with Biosolids Derived from Wastewater with Industrial Input.ACS environmental Au · 2026Article
- Long-Term Per- and Polyfluoroalkyl Substances Exposure and Kidney Function in Taiwanese Adolescents and Young Adults: A 10-Year Prospective Cohort Study.Journal of xenobiotics · 2026Article
- Article
- The effects of multi-generational exposure to Fluorine-Free Foam (F3) alternatives on Daphnia magna tolerance.Ecotoxicology (London, England) · 2025Article
- Review
- Comprehensive study of optical, photocatalytic and dielectric properties of CdScientific reports · 2025Article
- Draft genomes of three bacteria capable of growing on cocamidopropyl betaine orMicrobiology resource announcements · 2025Article
- Acoustic Waves and Their Application in Modern Fire Detection Using Artificial Vision Systems: A Review.Sensors (Basel, Switzerland) · 2025Review
- Highly Transparent Anti-Smudge Coatings for Self-Cleaning, Controllable Liquid Transport, and Corrosion Resistance.Polymers · 2025Article
- Assessing the effects of fluorine-free and PFAS-containing firefighting foams on development and behavioral responses using a zebrafish-based platform.Chemosphere · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This review provides a comparative analysis of the performance, toxicity, environmental impact, and health risks associated with fluorotelomer-based/short-chain AFFF and F3. Despite notable progress in F3 development, achieving comparable performance remains challenging in some cases. F3 formulations, while promising, are yet to be considered a direct replacement for AFFF in all Class B fire suppression scenarios due to variations in their performance across different fuel types and test conditions. Available studies indicate that commercially available F3 exhibit greater biodegradability and reduced environmental persistence compared to AFFF. However, some alternatives may still pose similar environmental impacts. Limited ecotoxicity studies suggest that some F3 may exhibit equal or even higher toxicity to aquatic species than short-chain (C6) AFFF. Toxicological assessments and risk evaluations of F3 should consider factors beyond environmental persistence, including acute and chronic ecotoxicity, potential endocrine disruption, and the full toxicological profile of foam formulations and their individual components. Further research is necessary to understand the fate, transport, bioaccumulation, and toxicity of F3 degradation products. Addressing these knowledge gaps is crucial to ensure the safe and sustainable implementation of F3 as an alternative fire suppression solution.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.